COSCIENS Biopharma (CSCI) Total Liabilities

Annual Total Liabilities

$2.71 M
-$1.31 M-32.54%

December 1, 2023

Summary

Performance

1-Year Change

-32.54%

3-Year Change

-29.76%

5-Year Change

+74.75%

15-Year Change

-35.34%

CSCI Total Liabilities Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

7.87%
CSCI annual total liabilities is higher than 7.87% of companies in Healthcare sector

High & Low

All-time High

$7.74 M
CSCI annual total liabilities is currently -65.01% below its historical high of $7.74 million

3-Year Low

$2.61 M
CSCI annual total liabilities is currently +3.61% above its 3-year low

Earnings dates

Last Annual Earnings Report Date

Dec 1, 2023
CSCI previous annual earnings announcement was published on Dec 1, 2023

Next Annual Earnings Report Date

N/A
CSCI next annual earnings announcement has not yet been scheduled

OtherCSCIbalance sheetmetrics:

Quarterly Current Liabilities

$8.17 M
CSCI quarterly total current liabilities is $8.17 million

Quarterly Long Term Liabilities

$15.59 M
CSCI quarterly total long term liabilities is $15.59 million

Quarterly Total Assets

$43.77 M
CSCI quarterly total assets is $43.77 million

Quarterly Current Assets

$28.22 M
CSCI quarterly total current assets is $28.22 million

Quarterly Total Liabilities

$23.75 M
-$63.00 K-0.26%

September 1, 2024

Summary

Performance

3-Month Change

-0.26%

1-Year Change

+777.64%

3-Year Change

+777.64%

5-Year Change

+777.64%

CSCI Quarterly Total Liabilities Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

36.87%
CSCI quarterly total liabilities is higher than 36.87% of companies in Healthcare sector

High & Low

All-time High

$23.82 M
CSCI quarterly total liabilities is currently -0.26% below its historical high of $23.82 million

3-Year Low

$2.54 M
CSCI quarterly total liabilities is currently +837.08% above its 3-year low

Earnings dates

Last Quarterly Earnings Report Date

Sep 1, 2024
CSCI previous earnings announcement was published on Sep 1, 2024

Next Quarterly Earnings Report Date

N/A
CSCI next earnings announcement has not yet been scheduled

OtherCSCIbalance sheetmetrics:

Quarterly Current Liabilities

$8.17 M
CSCI quarterly total current liabilities is $8.17 million

Quarterly Long Term Liabilities

$15.59 M
CSCI quarterly total long term liabilities is $15.59 million

Quarterly Total Assets

$43.77 M
CSCI quarterly total assets is $43.77 million

Quarterly Current Assets

$28.22 M
CSCI quarterly total current assets is $28.22 million

Total Liabilities Formula

Total Liabilities = Current Liabilities + Long-Term Liabilities

Annual Total Liabilities

$2.71 M
CSCI annual total liabilities is $2.71 million

Annual Current Liabilities

$4.54 M
CSCI annual total current liabilities is $4.54 million

Annual Total Long Term Liabilities

$1.40 M
CSCI annual total long term liabilities is $1.40 million

CSCI Total Liabilities Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterly
1 y1 year-32.5%+777.6%
3 y3 years-29.8%+777.6%
5 y5 years+74.8%+777.6%

CSCI Total Liabilities Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs low
3 y3-year-32.5%+3.6%-0.3%+837.1%
5 y5-year-32.5%+3.6%-0.3%+837.1%
alltimeall time-65.0%+302.0%-0.3%+4163.3%

COSCIENS Biopharma Total Liabilities History

DateAnnualQuarterly
Sep 2024
-
$23.75 M(-0.3%)
Jun 2024
-
$23.82 M(+839.6%)
Mar 2024
-
$2.54 M(-6.3%)
Dec 2023
$2.71 M(-32.5%)
$2.71 M(-7.6%)
Sep 2023
-
$2.93 M(+9.7%)
Jun 2023
-
$2.67 M(-21.6%)
Mar 2023
-
$3.41 M(-15.1%)
Dec 2022
$4.01 M(+53.6%)
$4.01 M(+39.9%)
Sep 2022
-
$2.87 M(-3.1%)
Jun 2022
-
$2.96 M(+11.5%)
Mar 2022
-
$2.65 M(+1.6%)
Dec 2021
$2.61 M(-32.2%)
$2.61 M(-30.2%)
Sep 2021
-
$3.74 M(+0.9%)
Jun 2021
-
$3.71 M(+2.3%)
Mar 2021
-
$3.63 M(-5.9%)
Dec 2020
$3.85 M(+1.5%)
$3.85 M(+19.3%)
Sep 2020
-
$3.23 M(+2.7%)
Jun 2020
-
$3.14 M(+1.6%)
Mar 2020
-
$3.09 M(-18.5%)
Dec 2019
$3.79 M(+145.0%)
$3.79 M(-6.2%)
Sep 2019
-
$4.05 M(+2.7%)
Jun 2019
-
$3.94 M(-1.3%)
Mar 2019
-
$3.99 M(+157.8%)
Dec 2018
$1.55 M(-63.0%)
$1.55 M(-31.3%)
Sep 2018
-
$2.26 M(-41.5%)
Jun 2018
-
$3.86 M(+2.5%)
Mar 2018
-
$3.76 M(-10.1%)
Dec 2017
$4.19 M(+41.0%)
$4.19 M(+58.0%)
Sep 2017
-
$2.65 M(+2.8%)
Jun 2017
-
$2.58 M(-4.9%)
Mar 2017
-
$2.71 M(-8.7%)
Dec 2016
$2.97 M(-47.4%)
$2.97 M(-24.1%)
Sep 2016
-
$3.91 M(-21.8%)
Jun 2016
-
$5.00 M(-12.7%)
Mar 2016
-
$5.73 M(+1.6%)
Dec 2015
$5.64 M(+17.1%)
$5.64 M(+12.9%)
Sep 2015
-
$5.00 M(-4.3%)
Jun 2015
-
$5.22 M(+9.9%)
Mar 2015
-
$4.75 M(-1.3%)
Dec 2014
$4.82 M(+5.7%)
$4.82 M(+3.1%)
Sep 2014
-
$4.67 M(-15.9%)
Jun 2014
-
$5.56 M(+16.8%)
Mar 2014
-
$4.76 M(+4.3%)
Dec 2013
$4.56 M(+17.1%)
$4.56 M(+61.9%)
Sep 2013
-
$2.81 M(-8.9%)
Jun 2013
-
$3.09 M(-0.8%)
Mar 2013
-
$3.11 M(-20.0%)
Dec 2012
$3.89 M(+8.8%)
$3.89 M(-0.3%)
Sep 2012
-
$3.90 M(+18.5%)
Jun 2012
-
$3.30 M(-12.1%)
Mar 2012
-
$3.75 M(+4.9%)
Dec 2011
$3.58 M(+3.0%)
$3.58 M(+12.4%)
Sep 2011
-
$3.18 M(-5.0%)
Jun 2011
-
$3.35 M(-4.0%)
Mar 2011
-
$3.49 M(+0.5%)
Dec 2010
$3.47 M
$3.47 M(-0.6%)
DateAnnualQuarterly
Sep 2010
-
$3.50 M(-3.6%)
Jun 2010
-
$3.63 M(-12.5%)
Mar 2010
-
$4.15 M(+4.8%)
Dec 2009
$3.96 M(-7.7%)
$3.96 M(+3.4%)
Sep 2009
-
$3.83 M(+6.5%)
Jun 2009
-
$3.59 M(-9.9%)
Mar 2009
-
$3.99 M(-7.0%)
Dec 2008
$4.29 M(+40.0%)
$4.29 M(+15.3%)
Sep 2008
-
$3.72 M(-0.9%)
Jun 2008
-
$3.75 M(+20.3%)
Mar 2008
-
$3.12 M(+1.8%)
Dec 2007
$3.06 M(+103.0%)
$3.06 M(+26.4%)
Sep 2007
-
$2.42 M(-8.9%)
Jun 2007
-
$2.66 M(+48.4%)
Mar 2007
-
$1.79 M(+18.8%)
Dec 2006
$1.51 M(-10.5%)
$1.51 M(+1.5%)
Sep 2006
-
$1.49 M(-21.9%)
Jun 2006
-
$1.90 M(+5.0%)
Mar 2006
-
$1.81 M(+7.6%)
Dec 2005
$1.69 M(+26.3%)
$1.69 M(+58.9%)
Sep 2005
-
$1.06 M(-16.2%)
Jun 2005
-
$1.27 M(-9.3%)
Mar 2005
-
$1.39 M(+4.5%)
Dec 2004
$1.33 M(+98.1%)
$1.33 M(+51.2%)
Sep 2004
-
$882.30 K(+5.8%)
Jun 2004
-
$834.30 K(+49.7%)
Mar 2004
-
$557.20 K(-17.2%)
Dec 2003
$673.30 K(-18.4%)
$673.30 K(+7.3%)
Sep 2003
-
$627.70 K(-24.2%)
Jun 2003
-
$828.60 K(-12.1%)
Mar 2003
-
$942.20 K(+14.2%)
Dec 2002
$824.70 K(-13.1%)
$824.70 K(-2.9%)
Sep 2002
-
$849.30 K(-20.1%)
Jun 2002
-
$1.06 M(+12.3%)
Mar 2002
-
$946.90 K(-0.2%)
Dec 2001
$948.90 K(-47.0%)
$948.90 K(-6.7%)
Sep 2001
-
$1.02 M(-19.9%)
Jun 2001
-
$1.27 M(-25.2%)
Mar 2001
-
$1.70 M(-5.2%)
Dec 2000
$1.79 M(+18.4%)
$1.79 M(-4.4%)
Sep 2000
-
$1.87 M(+2.8%)
Jun 2000
-
$1.82 M(+5.9%)
Mar 2000
-
$1.72 M(+13.8%)
Dec 1999
$1.51 M(+45.5%)
$1.51 M(+16.9%)
Sep 1999
-
$1.29 M(+12.2%)
Jun 1999
-
$1.15 M(-3.3%)
Mar 1999
-
$1.19 M(+14.7%)
Dec 1998
$1.04 M(-59.8%)
$1.04 M(-11.8%)
Sep 1998
-
$1.18 M(-57.7%)
Jun 1998
-
$2.79 M(+4.3%)
Mar 1998
-
$2.68 M(+3.5%)
Dec 1997
$2.59 M(-66.6%)
$2.59 M(-70.7%)
Sep 1997
-
$8.83 M(+15.0%)
Jun 1997
-
$7.68 M(+4.9%)
Mar 1997
-
$7.32 M
Dec 1996
$7.74 M
-

FAQ

  • What is COSCIENS Biopharma annual total liabilities?
  • What is the all time high annual total liabilities for COSCIENS Biopharma?
  • What is COSCIENS Biopharma annual total liabilities year-on-year change?
  • What is COSCIENS Biopharma quarterly total liabilities?
  • What is the all time high quarterly total liabilities for COSCIENS Biopharma?
  • What is COSCIENS Biopharma quarterly total liabilities year-on-year change?

What is COSCIENS Biopharma annual total liabilities?

The current annual total liabilities of CSCI is $2.71 M

What is the all time high annual total liabilities for COSCIENS Biopharma?

COSCIENS Biopharma all-time high annual total liabilities is $7.74 M

What is COSCIENS Biopharma annual total liabilities year-on-year change?

Over the past year, CSCI annual total liabilities has changed by -$1.31 M (-32.54%)

What is COSCIENS Biopharma quarterly total liabilities?

The current quarterly total liabilities of CSCI is $23.75 M

What is the all time high quarterly total liabilities for COSCIENS Biopharma?

COSCIENS Biopharma all-time high quarterly total liabilities is $23.82 M

What is COSCIENS Biopharma quarterly total liabilities year-on-year change?

Over the past year, CSCI quarterly total liabilities has changed by +$21.05 M (+777.64%)